Published Online: January 20, 2014. doi:10.1001/jamaneurol.2013.5378.
Study concept and design: Mead, Brandner, Collinge.
Acquisition of data: Mead, Wadsworth, Porter, Linehan, Pietkiewicz, Jackson, Brandner.
Analysis and interpretation of data: Mead, Wadsworth, Linehan, Jackson, Brandner, Collinge.
Drafting of the manuscript: Mead, Wadsworth, Brandner.
Critical revision of the manuscript for important intellectual content: All authors.
Obtained funding: Brandner, Collinge.
Administrative, technical, and material support: Mead, Wadsworth, Linehan, Pietkiewicz, Jackson, Brandner.
Study supervision: Mead, Brandner, Collinge.
Conflict of Interest Disclosures: Prof Collinge is a director and Drs Wadsworth and Jackson and Prof Collinge are shareholders and consultants of D-Gen Limited, an academic spinout company working in the field of prion disease diagnosis, decontamination, and therapeutics. D-Gen markets the ICSM35 antibody used in this study. Some of the work, including that undertaken as part of the National Prion Monitoring Cohort Study and by Prof Brandner, was funded by the Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme. No other disclosures were reported.
Funding/Support: The clinical research work was funded by the Medical Research Council and Department of Health (England).
Role of the Sponsor: The Medical Research Council and Department of Health (England) had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the patient and his family for generously consenting to use of human tissues in this study. We are grateful for the contributions of several physicians who were involved in patient care and colleagues from the National CJD Research and Surveillance Unit.